17,261 trials
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1) — 1; 8; 1; 12 participants
Dyslipidemias · Diabetes Mellitus, Type 2
Primary: The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment — 0.00; 0.04; -0.04; 0.00 mmol/l — p=0.766
Knee Osteoarthritis
Primary: Change of Pain Over 26 Weeks (Change From Baseline) — -4.13; -4.00; -4.90 units on a scale
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria — 2 participants
Multiple Myeloma
Primary: Phase I - Maximum Planned Dose (MPD) Level — 4 Dosing Level
Fatty Liver
Primary: Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels — -0.68; -0.28; 0.65; 6.36 percentage change — p=0.222
Estrogen Receptor-negative Breast Cancer · Male Breast Cancer · Progesterone Receptor-negative Breast Cancer
Primary: Disease Control Rate (DCR) — 0 participants
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
Lymphoproliferative Disorder
Primary: Event-free Survival — 71 percentage of participants analyzed
Hemophilia A
Primary: The Area Under the Concentration Curve for Human-cl rhFVIII Compared to Kogenate FS — 0.39; 0.38 h IU/mL (IU/kg)
COPD
Primary: FEV1, E0-4; the Average Value at Visit 5 From Before to 4 Hours After Morning Dose (Peak Effect) — 0.21; 0.17; 0.14; 0.16 Litre
Neuroblastoma
Primary: Overall Response - Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR) — 5; 3 participants
Acne Vulgaris
Primary: Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules). — -7.8; -15.6 lesion count — p=0.006
Neuroblastoma
Primary: Number of Responders (Response Rate) — 0; 5; 13; 18 participants